Concepedia

David C. Griffith

DC

45

Publications

3.4K

Citations

24

H-Index

1997

Active since

Affiliations

Doctors Company (United States)(Current)

Mapp Biopharmaceutical (United States)

Institute for Clinical Pharmacodynamics (United States)

Essential Research (United States)

Nemours Children's Clinic

David C. Griffith is an author at Doctors Company (United States) specializing in pharmacology, medicine, and antibiotics.

Top concepts

Publications per year

1997–2022

45

Publications

45

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Richard G. Wunderink, Evangelos J. Giamarellos‐Bourboulis, Galia Rahav et al. · Infectious Diseases and Therapy · 2018 · 418 citations · Full text

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

Scott J. Hecker, K. Raja Reddy, Maxim Totrov et al. · Journal of Medicinal Chemistry · 2015 · 388 citations · Full text

, , +22

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

Olga Lomovskaya, Dongxu Sun, Debora Rubio-Aparicio et al. · Antimicrobial Agents and Chemotherapy · 2017 · 337 citations · Full text

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis et al. · JAMA · 2018 · 298 citations · Full text

REVIEW OF REPORTED CHOLERA OUTBREAKS WORLDWIDE, 1995–2005

David C. Griffith, Louise A. Kelly‐Hope, Mark A. Miller · American Journal of Tropical Medicine and Hygiene · 2006 · 223 citations

, , +14

Rows per page

1–5 of 45